B1962 (Not yet branded)
Other Medications
Description
B1962 is a novel therapeutic agent administered as an injection for the treatment of advanced malignant solid tumors, including advanced colorectal cancer. Based on its development in tumor-agnostic and CRC-specific Phase II clinical trials, this compound appears to target mechanisms relevant across multiple cancer types. The drug has completed Phase IIa evaluation in advanced solid tumors and proceeded to Phase IIb testing specifically in advanced colorectal cancer patients.
Mechanism of Action
The specific molecular mechanism of action for B1962 has not been publicly disclosed in available clinical trial documentation. Given its evaluation in both tumor-agnostic and colorectal cancer-specific settings, it likely targets a fundamental oncogenic pathway or cellular process common across multiple cancer types.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.